These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 24896369)

  • 1. The administration of L-thyroxine as soft gel capsule or liquid solution.
    Vita R; Fallahi P; Antonelli A; Benvenga S
    Expert Opin Drug Deliv; 2014 Jul; 11(7):1103-11. PubMed ID: 24896369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advancements in the treatment of hypothyroidism with L-T4 liquid formulation or soft gel capsule: an update.
    Fallahi P; Ferrari SM; Ruffilli I; Ragusa F; Biricotti M; Materazzi G; Miccoli P; Antonelli A
    Expert Opin Drug Deliv; 2017 May; 14(5):647-655. PubMed ID: 27552635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Stability of TSH, and Thyroid Hormones, in Patients Treated With Tablet, or Liquid Levo-Thyroxine.
    Antonelli A; Elia G; Ragusa F; Paparo SR; Cavallini G; Benvenga S; Ferrari SM; Fallahi P
    Front Endocrinol (Lausanne); 2021; 12():633587. PubMed ID: 33790863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel formulation of L-thyroxine (L-T4) reduces the problem of L-T4 malabsorption by coffee observed with traditional tablet formulations.
    Vita R; Saraceno G; Trimarchi F; Benvenga S
    Endocrine; 2013 Feb; 43(1):154-60. PubMed ID: 22932947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. L-T4 Therapy in Enteric Malabsorptive Disorders.
    Fallahi P; Ferrari SM; Elia G; Ragusa F; Paparo SR; Antonelli A
    Front Endocrinol (Lausanne); 2021; 12():626371. PubMed ID: 33708175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and Clinical Implications of Two Non-Tablet Oral Formulations of L-Thyroxine in Patients with Hypothyroidism.
    Trimboli P; Mouly S
    J Clin Med; 2022 Jun; 11(12):. PubMed ID: 35743549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversible normalisation of serum TSH levels in patients with autoimmune atrophic gastritis who received L-T4 in tablet form after switching to an oral liquid formulation: a case series.
    Fallahi P; Ferrari SM; Ruffilli I; Antonelli A
    BMC Gastroenterol; 2016 Feb; 16():22. PubMed ID: 26965518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral L-thyroxine liquid versus tablet in patients with hypothyroidism without malabsorption: a prospective study.
    Fallahi P; Ferrari SM; Antonelli A
    Endocrine; 2016 Jun; 52(3):597-601. PubMed ID: 26721663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liquid L-thyroxine versus tablet L-thyroxine in patients on L- thyroxine replacement or suppressive therapy: a meta-analysis.
    Laurent I; Tang S; Astère M; Wang KR; Deng S; Xiao L; Li QF
    Endocrine; 2018 Jul; 61(1):28-35. PubMed ID: 29572710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching levothyroxine from the tablet to the oral solution formulation corrects the impaired absorption of levothyroxine induced by proton-pump inhibitors.
    Vita R; Saraceno G; Trimarchi F; Benvenga S
    J Clin Endocrinol Metab; 2014 Dec; 99(12):4481-6. PubMed ID: 25259910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liquid and softgel capsules of l-thyroxine results lower serum thyrotropin levels more than tablet formulations in hypothyroid patients.
    Benvenga S
    J Clin Transl Endocrinol; 2019 Dec; 18():100204. PubMed ID: 31844631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TSH Normalization in Bariatric Surgery Patients After the Switch from L-Thyroxine in Tablet to an Oral Liquid Formulation.
    Fallahi P; Ferrari SM; Camastra S; Politti U; Ruffilli I; Vita R; Navarra G; Benvenga S; Antonelli A
    Obes Surg; 2017 Jan; 27(1):78-82. PubMed ID: 27272506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tablet levothyroxine (L-T4) malabsorption induced by proton pump inhibitor; a problem that was solved by switching to L-T4 in soft gel capsule.
    Vita R; Benvenga S
    Endocr Pract; 2014 Mar; 20(3):e38-41. PubMed ID: 24246350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to levothyroxine in a bariatric surgery patient: an indication for liquid formulation?
    Hommel C; Delgrange E
    Acta Clin Belg; 2017 Feb; 72(1):72-75. PubMed ID: 27362875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expert opinion on liquid L-thyroxine usage in hypothyroid patients and new liquid thyroxine formulation - Tirosint SOL [Opinia ekspertów dotycząca stosowania płynnej postaci lewotyroksyny oraz nowego preparatu Tirosint SOL u chorych na niedoczynność tarczycy].
    Gietka-Czernel M; Hubalewska-Dydejczyk A; Kos-Kudła B; Lewiński A; Ruchała M; Syrenicz A; Zgliczyński W
    Endokrynol Pol; 2020; 71(5):441-465. PubMed ID: 33202031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of total thyroxine in dogs after administration of an oral solution of levothyroxine sodium.
    Le Traon G; Burgaud S; Horspool LJ
    J Vet Pharmacol Ther; 2008 Apr; 31(2):95-101. PubMed ID: 18307500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral liquid levothyroxine treatment at breakfast: a mistake?
    Cappelli C; Pirola I; Gandossi E; Formenti A; Castellano M
    Eur J Endocrinol; 2014 Jan; 170(1):95-9. PubMed ID: 24123095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medication adherence and the use of new pharmaceutical formulations: the case of levothyroxine.
    Scavone C; Sportiello L; Cimmaruta D; Sullo MG; Vitelli B; Rafaniello C; Fossati T; Rossi F
    Minerva Endocrinol; 2016 Jun; 41(2):279-89. PubMed ID: 27015567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of a Liquid Formulation of Levo-thyroxine in Differentiated Thyroid Cancer Patients.
    Giusti M; Mortara L; Machello N; Monti E; Pera G; Marenzana M
    Drug Res (Stuttg); 2015 Jun; 65(6):332-6. PubMed ID: 25020105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liquid and softgel levothyroxine use in clinical practice: state of the art.
    Virili C; Trimboli P; Romanelli F; Centanni M
    Endocrine; 2016 Oct; 54(1):3-14. PubMed ID: 27473098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.